REGN News and Press, Regeneron Pharmaceuticals Inc. From 02/09/24

2024-02-09 06:45:00 ET Diabetes and weight-loss medicines surged in popularity last year. Few garnered nearly as much attention as Ozempic, a therapy marketed by Denmark-based biotech giant Novo Nordisk . Ozempic addresses a real problem. Diabetes and obesity have been on the rise for d...

2024-02-06 15:27:22 ET More on Veru Seeking Alpha’s Quant Rating on Veru Historical earnings data for Veru Financial information for Veru Read the full article on Seeking Alpha For further details see: Veru eyes better weight loss drugs as ...

2024-02-06 06:45:00 ET For moves that don't improve the underlying strength of a company's business, stock splits garner a lot of attention, at least when conducted by prominent corporations. In part, that's because they make it easier for investors on a budget to purchase a single share. S...

2024-02-02 12:43:50 ET Summary Regeneron returned to topline growth in 2023 and this has led to the company's valuation rising to my expected EV/revenue range. The company is making significant investments in the obesity space, focusing on preserving lean mass and reducing fat mas...

2024-02-02 11:59:04 ET Regeneron Pharmaceuticals, Inc. (REGN) Q4 2023 Earnings Conference Call February 2, 2024 8:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations Leonard Schleifer - President and Chief Executive Officer George...

2024-02-02 07:17:52 ET More on Regeneron Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals Inc. (REGN) American Society o...

2024-02-02 07:13:00 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals Inc. (REGN) Am...

2024-02-02 06:32:56 ET More on Regeneron Pharmaceuticals Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) 2seventy stock rises as Regeneron acquires R&D assets Read the full article on Seeking Alpha For further details see: Re...

Atlas Lithium Corporation (ATLX) is expected to report $-0.47 for Q4 2023 Capital Product Partners L.P. (CPLP) is expected to report $0.7 for Q4 2023 WisdomTree Inc. (WT) is expected to report $0.11 for Q4 2023 Mitsubishi Corporation (MSBHF) is expected to report for Q3 2024 C3is ...

TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for linvoseltamab to treat adult patients with relapsed/refrac...